PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
N Engl J Med. Author manuscript; available in PMC 2014 April 9.
Published in final edited form as:
PMCID: PMC3980568
NIHMSID: NIHMS563439

TREM2 and Neurodegenerative Disease

Christiane Reitz, M.D., Ph.D. and Richard Mayeux, M.D., for the Alzheimer’s Disease Genetics Consortium

TO THE EDITOR

Guerreiro et al.1 and Jonsson et al.2 (Jan. 10 issue) report an association between the single-nucleotide polymorphism (SNP) rs75932628 in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2) (predicting an R47H substitution) and Alzheimer’s disease in persons of European ancestry.

We and other members of the Alzheimer’s Disease Genetics Consortium assembled multiple data sets from a total of 5896 black patients (1968 cases and 3928 controls). First, the association of Alzheimer’s disease with genotyped and imputed SNPs was individually assessed in each data set with the use of logistic regression for case–control data sets and generalized estimating equations for family-based data sets (with adjustment for age, sex, the presence or absence of the apolipoprotein E [APOE] ε4 allele, and population stratification). The results from the individual data sets were combined in a genomewide inverse-variance-weighted meta-analysis. Subsequently, a versatile gene-based association study (VEGAS)3 was performed specifically to explore the association of the TREM2 gene with Alzheimer’s disease; the addition of 20 kb to each side yielded a list of SNPs (see the Supplementary Appendix, available with the full text of this letter at NEJM.org). With the use of simulation based on the linkage-disequilibrium structure of a group of reference samples from HapMap, VEGAS allowed us to calculate the empirical P value for associations between disease status and variants in TREM2 while taking into account gene size and linkage disequilibrium between the markers.3

The TREM2 SNP described by Guerreiro et al. and Jonsson et al. (rs75932628) did not pass quality control because of a low minor allele frequency (0.0009). However, in the genomewide meta-analyses of the results from the individual data sets, five SNPs in the TREM2 region were associated with Alzheimer’s disease at a P value of less than 0.009; the G allele of rs7748513 was most strongly associated with affected status (odds ratio ±SE, 1.16±0.05; P = 0.001). This SNP is located 1 kb downstream of and in linkage disequilibrium with rs75932628. In the VEGAS analyses in which linkage disequilibrium between the markers was taken into account, the TREM2 gene was significantly associated with Alzheimer’s disease (P<0.001). Also, in these analyses, the strongest single-marker association was observed for rs7748513 (P = 0.001). Finally, in VEGAS analyses that were restricted to the largest individual data set (907 cases and 1675 controls), the TREM gene remained significantly associated with Alzheimer’s disease (P = 0.04). This genetic study of Alzheimer’s disease in blacks provides support for a role of TREM2 in Alzheimer’s disease.

Supplementary Material

Supplementary data

Footnotes

Members of the Alzheimer’s Disease Genetics Consortium are listed in the Supplementary Appendix, available at NEJM.org.

No potential conflict of interest relevant to this letter was reported.

References

1. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368:117–27. [PMC free article] [PubMed]
2. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013;368:107–16. [PMC free article] [PubMed]
3. Liu JZ, McRae AF, Nyholt DR, et al. A versatile gene-based test for genome-wide association studies. Am J Hum Genet. 2010;87:139–45. [PubMed]